Ergomed Expands U.S. Presence with New Office in Boston
Guildford, United Kingdom February 9, 2024 – ERGOMED Group Limited (“Ergomed”), a global provider of specialized services to the biotechnology and pharmaceutical industry, announces a significant milestone in its continued growth strategy in the United States with the opening of a new office at Kendall Square in Cambridge, MA.
Building upon our established presence in Raleigh, North Carolina, this expansion is a strategic move to better support our customers and enhance our footprint in key biotech and pharma locations across the United States. Ergomed has been an integral part of the U.S. market for years, and the decision to open an office in Boston aligns with our commitment to providing unparalleled solutions in both Oncology as well as in Rare and Complex Diseases, to the local biotechnology community.
Strategic Expansion: Our new presence in Boston is a testament to Ergomed’s commitment in meeting the evolving needs of our clients in key biotech/pharma hubs across the United States.
Specialized Therapeutic Focus: Opening an additional office in US aligns with Ergomed’s mission and vision to more closely support companies advancing research in Oncology as well as in Rare and Complex Diseases, which are all strongly represented in the local Boston biotechnology hub.
Dave Selkirk, President of Ergomed Clinical Research, shared his excitement about the new facility, stating, “Our continued growth in the U.S. comes from our focus on delivery in Oncology as well as in Rare and Complex Diseases. The new office in Boston, a renowned hub for innovation, positions us to be at the forefront of the biotech/pharma industry. It will facilitate increased collaboration with our sponsor partners, ensuring they receive the highest level of both scientific guidance and operational excellence.“
This expansion not only signifies an achievement for Ergomed but also reflects the company’s long-standing dedication to the vitally important U.S. biotechnology community.
Founded in 1997, Ergomed is dedicated to the provision of global specialized services in the pharmaceutical and biotech industry. Today, Ergomed supports pharmaceutical companies with services spanning all phases of clinical trials, post-approval pharmacovigilance, and medical information.
Recognized internationally in both rare disease and oncology drug development for its expertise, Ergomed offers a full range of quality clinical research and clinical trial management services along with an industry-leading suite of specialized pharmacovigilance solutions.
By providing this full-service offering, Ergomed enables emerging and established life sciences companies to meet their regulatory obligations, maximize their drug development success and their product value.
For more information email firstname.lastname@example.org.